A new treatment option has become available for severe epilepsy: fenfluramine, which is now available on the NHS ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

The drug is the first non-cannabinoid option for patients with LGS and an alternative to Jazz Pharma's Epidyolex (cannabidiol ...

Hundreds of children with severe epilepsy will be able to benefit from a groundbreaking new treatment on the NHS that could significantly reduce their seizures, providing new hope for them and their ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

“The recent FDA approval for formulations containing CBD, such as Epidiolex used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in ...

However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...

Plymouth Meeting’s Harmony Biosciences’ stock fell 10% on Wednesday after the FDA rejected the expansion of its insomnia drug ...

Bexicaserin is being developed to treat a group of disorders known as developmental and epileptic encephalopathies (DEEs), including Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis ...

Through the acquisition, Lundbeck gains access to bexicaserin, which is being developed to treat seizures associated with Dravet syndrome, Lennox Gastaut syndrome and other rare epilepsies.